Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer - Aguado - 2021 - Molecular Oncology - Wiley Online Library
Read in JCO:... - American Society of Clinical Oncology | Facebook
new-molecular-drivers-in-nsclc-the-role-of-met
IJMS | Free Full-Text | Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ on Twitter: "Great slides @ChristianRolfo on diagnostic challenges on MET amplification. #biomarker #lcsm #LungCancer https://t.co/zH1x2zrxYS" / Twitter
Cancers | Free Full-Text | MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
![PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5c15af3c1bcc3bda3026ee7e5197328b2b922d57/5-Table1-1.png "PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar")
PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar
The multiple paths towards MET receptor addiction in cancer | Oncogene
Frontiers | I-125 seeds brachytherapy combined with immunotherapy for MET amplification in non-small cell lung cancer from clinical application to related lncRNA mechanism explore: a case report
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
An overview of the c-MET signaling pathway - Shawna Leslie Organ, Ming-Sound Tsao, 2011
Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy | Journal of Medicinal Chemistry
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Cancers | Free Full-Text | Targeting MET Amplification as a New Oncogenic Driver
Targeted Therapies Expanding for MET Dysregulation in NSCLC - ILCN.org (ILCN/WCLC)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
CytoCell C-MET (MET) Amplification FISH Probe | OGT
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
